Marcella V.
- Country
- Italy
- Department
- Neurologia
Research Overview
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Asundexian for Ischemic Stroke Prevention in Adults Post-Acute Non-Cardioembolic Stroke or High-Risk TIA
- Randomized Phase II/III Trial Evaluating Acetylcarnitine Hydrochloride on Functional Disability Progression in Amyotrophic Lateral Sclerosis Patients
Data & Insights
Has run more than one trial at 2 of 278 partner sites.
Specializations
Neurodegenerative Disorders
The investigator specializes in researching therapeutic approaches for amyotrophic lateral sclerosis (ALS), with particular focus on evaluating treatments that may slow disease progression and maintain functional capabilities.
- ALS Treatment Development
- Functional Disability Assessment
- Therapeutic Compound Evaluation
Their work involves investigating metabolic compounds and their potential neuroprotective effects in ALS patients.
Cerebrovascular Medicine
The investigator focuses on advancing treatments for acute ischemic stroke and transient ischemic attack (TIA), with emphasis on preventive therapeutic strategies.
- Stroke Prevention
- Antithrombotic Therapy
- Post-Stroke Care
Their research extends to innovative anticoagulation approaches and bleeding risk assessment in stroke patients.
Clinical Therapeutics
The investigator conducts research in novel therapeutic interventions across neurological conditions, focusing on both metabolic and antithrombotic treatments.
- Drug Safety Assessment
- Treatment Efficacy Studies
- Patient Outcome Evaluation
Their work encompasses comprehensive assessment of therapeutic compounds in neurological disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.